Jennewein Biotechnologie obtains EU approval for 2’-fucosyllactose
Advertisement
Jennewein Biotechnologie , the world’s leading manufacturer of human milk oligosaccharides (HMOs), today announces that it has received a response from the European Commission which includes the decision that “2'-fucosyllactose powder and liquid concentrate may be placed on the European Union market as a novel food ingredient.” This follows a decision by the Committee on Safety Assessment of Novel Foods (VNV) to issue a certificate in September 2016 stating that the Jennewein product is “…a well-characterized 2'-fucosyllactose preparation of high purity.” The VNV based its notification on European Commission Regulation 258/97 and a dossier provided by Jennewein Biotechnologie containing specific technical information about the product. This confirms that Jennewein’s 2'-fucosyllactose, which is produced using a bacterial fermentation process, is the first HMO to receive a novel food authorization under EU law and can now enter the market in Europe. The registration of this HMO will revolutionize the EU infant formula market.:“This Novel Food authorization is a milestone in the history of biotechnology, and a major breakthrough in the development of infant formulas,” stated Stefan Jennewein, the CEO of Jennewein Biotechnologie GmbH.
Jennewein Biotechnologie GmbH
About 2'-fucosyllactose
The oligosaccharide 2'-fucosyllactose is the most abundant HMO. Several beneficial functions have been attributed to 2'-fucosyllactose, including prebiotic activity, protection against infection by diarrhea-causing pathogens, the attenuation of inflammation, and the promotion of brain development in terms of learning and memory. These functional benefits underlie the great demand for 2'-fucosyllactose as a functional ingredient in infant formula and therapeutic nutrition products.
Most read news
Other news from the department business & finance
Get the food & beverage industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sustainable vanilla cultivation on fallow land
Kellogg's files lawsuit against its striking cereal workers
Food security: Irradiation and essential oil vapors for cereal treatment - A combined treatment of irradiation and essential oil vapors could effectively eliminate insects, bacteria and mold in stored grains
Food in sight? The liver is already active! - Adaptation of the sugar metabolism begins in the brain
QUT develops golden bananas high in pro-vitamin A
Mars: Grant F. Reid decides to hand over the reins as CEO - Poul Weihrauch to take on role from end of September
Zenon as cockpit of key figures for the Smart Factory
NETZSCH invests 50 million euros in the plant centralization in Waldkraiburg - NETZSCH intends to further expand the global market leadership for its pumps
New olive oil created by CSIC helps prevent type 2 diabetes